How should I further manage a patient with a triglyceride level now 311 mg/dL (down from 400 mg/dL) who is taking rosuvastatin (Crestor) and ezetimibe (Zetia)?

Management Recommendation

Add icosapent ethyl (IPE) to the current regimen of rosuvastatin and ezetimibe, after confirming medication adherence, optimizing lifestyle interventions, and ruling out secondary causes of hypertriglyceridemia. 1

Current Status Assessment

Your patient has made progress (triglycerides decreased from 400 to 311 mg/dL), but persistent triglycerides ≥150 mg/dL indicate residual cardiovascular risk despite statin and ezetimibe therapy. The 2021 ACC Expert Consensus specifically addresses this clinical scenario 1.

Step-by-Step Management Algorithm

1. Verify LDL-C Control First

• Check if LDL-C is adequately controlled on current rosuvastatin + ezetimibe therapy
• If LDL-C remains ≥70 mg/dL in very high-risk patients (or ≥100 mg/dL in other ASCVD patients), optimize LDL-lowering before addressing triglycerides 1, 2
• Consider increasing rosuvastatin dose or adding PCSK9 inhibitor if LDL-C goals not met

2. Reassess Lifestyle and Secondary Causes

Once LDL-C is optimized, the guideline mandates reassessing 1:

• Medication adherence to current regimen
• Lifestyle factors: Diet quality, alcohol intake (especially important for triglycerides), physical activity, weight management
• Secondary causes: Uncontrolled diabetes, hypothyroidism, kidney disease, medications that raise triglycerides (thiazides, beta-blockers, estrogens, corticosteroids)

3. Add Icosapent Ethyl (IPE)

If triglycerides remain ≥150 mg/dL after steps 1-2, it is reasonable to add icosapent ethyl 2 grams twice daily 1. This recommendation is based on:

• The REDUCE-IT trial showing cardiovascular outcomes benefit
• Specific indication for patients with controlled LDL-C on statin therapy but persistent triglycerides 150-499 mg/dL
• Your patient at 311 mg/dL falls squarely in this range

Important Clinical Nuances

The rosuvastatin-ezetimibe combination is already optimal for LDL-C lowering 3, 4. Recent real-world data shows this combination reduces LDL-C by 23-27% and triglycerides by 4-7% 3. The combination is particularly effective in patients with diabetes or metabolic syndrome, providing 19-24% triglyceride reduction 4.

Do not add fibrates to this regimen. While fibrates lower triglycerides, the 2021 guideline prioritizes IPE over fibrates for cardiovascular risk reduction in patients already on statin therapy with persistent moderate hypertriglyceridemia 1.

Risk Stratification Matters

The aggressiveness of triglyceride management depends on ASCVD risk 1:

• Very high-risk patients (recurrent ASCVD events or ASCVD with high-risk conditions): More aggressive triglyceride management warranted
• Other ASCVD patients: Still benefit from IPE if triglycerides remain ≥150 mg/dL on optimized LDL therapy

Common Pitfalls to Avoid

• Don't add another statin or increase rosuvastatin excessively just for triglycerides—statins have modest triglyceride-lowering effects (7-30% depending on dose)
• Don't use omega-3 supplements from health food stores—only prescription IPE (icosapent ethyl) has cardiovascular outcomes data
• Don't ignore lifestyle modification—dietary changes and alcohol reduction can substantially lower triglycerides and are foundational 1, 5
• Don't forget to monitor liver enzymes when using combination lipid therapy 6

Monitoring Plan

• Recheck fasting lipid panel in 4-12 weeks after any intervention
• Monitor for muscle symptoms (myopathy risk with statin-ezetimibe combination) 6
• Assess medication adherence at each visit—single-pill combinations improve adherence 7